Browse CD247

Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF02189 Immunoreceptor tyrosine-based activation motif
PF11628 T-cell surface glycoprotein CD3 zeta chain
Function

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:2470098, PubMed:7509083). CD3Z ITAMs phosphorylation creates multiple docking sites for the protein kinase ZAP70 leading to ZAP70 phosphorylation and its conversion into a catalytically active enzyme (PubMed:7509083). Plays an important role in intrathymic T-cell differentiation. Additionally, participates in the activity-dependent synapse formation of retinal ganglion cells (RGCs) in both the retina and dorsal lateral geniculate nucleus (dLGN) (By similarity).

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002831 regulation of response to biotic stimulus
GO:0006909 phagocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0009615 response to virus
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0042110 T cell activation
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045785 positive regulation of cell adhesion
GO:0050688 regulation of defense response to virus
GO:0050690 regulation of defense response to virus by virus
GO:0050792 regulation of viral process
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051607 defense response to virus
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0098542 defense response to other organism
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function -
Cellular Component GO:0042101 T cell receptor complex
GO:0042105 alpha-beta T cell receptor complex
GO:0043235 receptor complex
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1643685: Disease
R-HSA-202424: Downstream TCR signaling
R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-202433: Generation of second messenger molecules
R-HSA-162906: HIV Infection
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-164944: Nef and signal transduction
R-HSA-389948: PD-1 signaling
R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029485: Role of phospholipids in phagocytosis
R-HSA-202403: TCR signaling
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis
R-HSA-202430: Translocation of ZAP-70 to Immunological synapse
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD247 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD247 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27549124Sarcoma; NeuroblastomaPromote immunity (T cell function); essential for immunotherapyT cells engineered to express a third-generation GD2-CAR incorporating the 14g2a-scFv with the CD28, OX40, and CD3ζ signaling domains (14g2a.CD28.OX40.ζ) mediated efficient and comparable lysis of both GD2+ sarcoma and neuroblastoma cell lines in vitro
25049283neuroblastomaPromote immunity (T cell function); essential for immunotherapyWe compared CAR.GD2 constructs that encoded the CD3ζ chain alone, with CD28, 4-1BB, or CD28 and 4-1BB costimulatory endodomains. CAR.GD2 expression rendered NKT cells highly cytotoxic against NB cells without affecting their CD1d-dependent reactivity. We observed a striking T helper 1-like polarization of NKT cells by 4-1BB-containing CARs. Importantly, expression of both CD28 and 4-1BB endodomains in the CAR.GD2 enhanced in vivo persistence of NKT cells. These CAR.GD2 NKT cells effectively localized to the tumor site had potent antitumor activity, and repeat injections significantly improved the long-term survival of mice with metastatic NB.
24986688melanomaPromote immunityCompared with CARs containing the CD3ζ chain alone, or in tandem with the CD28 or the 4-1BB intracellular domains, ICOS signaling increased IL-17A, IL-17F, and IL-22 following antigen recognition.
25209187colorectal carcinomaPromote immunityOur initial studies with patients with stage IV colorectal cancer show that before treatment the patients displayed an immunosuppressive status indicated by elevated MDSC levels and the downregulated CD247 expression, which is critical for T-cell and NK cell activities.
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD247 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD247 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0270.958
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1370.908
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0530.955
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3010.58
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8410.451
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3760.792
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7790.194
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.010.307
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5360.614
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5160.246
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.650.755
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1250.544
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD247 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD247. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD247. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD247.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD247. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD247 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD247 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD247
NameCD247 molecule
Aliases CD3H; CD3Q; CD3Z; CD3z antigen, zeta polypeptide (TiT3 complex); CD247 antigen; CD3-ZETA; IMD25; T3Z; TCRZ; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD247 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD247.
ID Name Drug Type Targets #Targets
DB00075MuromonabBiotechC1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......15